Dong-Ho Nahm (0000-0001-5253-6577)

Personal information

Biography

Curriculum vitae

Dr. Dong-Ho Nahm received his M.D. title from Yonsei University Medical College in 1989, and his M.S. title by the study on the <antigen-binding characteristics of anti-neuronal cell autoantibody in systemic lupus erythematosus>, and his Ph.D. title by the study on the <house dust mite antigen-specific immune complex in the serum samples of patients with bronchial asthma> from Yonsei University Graduate School, Korea, in 1992 and 1995, respectively.

He received Board of lnternal Medicine in 1994 and received Board of Allergy and Clinical lmmunology in 1998.

He has been involved in the in-patient and out-patient care of patients with allergic and rheumatic diseases in the Department of Allergy and Clinical Immunology in Ajou University Hospital, Korea from 1995 to the present.

He received Post-Doctoral Fellow training at Laboratory of Allergic Diseases (LAD) of National lnstitutes of Health (NIH), Bethesda, USA from 2002 to 2003 and carried out a proteomics study to identify the proteins involved in the signaling pathway in mast cells using mass spectrometry analysis.

Current research topic is a development of a new personalized immunomodulatory therapy for atopic dermatitis.

[Major clinical and research contributions]

Dr. Dong-Ho Nahm and colleagues
(1) identified a cytokeratin 18 protein as an airway epithelial autoantigen associated with nonallergic asthma in 2002,
(2) identified an alpha-enolase protein as an autoantigen associated with severe asthma in 2006,
(3) developed a modified immunotherapy for severe refractory atopic dermatitis with a combination of allergen immunotherapy and histamine-immunoglobulin complex in 2008,
(4) have been trying to develop a new personalized immunomodulatory therapy for atopic dermatitis since 2011.

Activities

Collapse all

Frontiers in Allergy: Lausanne, CH

2021-04-13 to present | Review Editor

Employment

Dong-Ho Nahm

https://orcid.org/0000-0001-5253-6577

Personal information

Countries

Biography

Activities

Employment (18)

Frontiers in Allergy: Lausanne, CH

Allergy, Asthma & Immunology Research: Suwon, KR

Ajou University Hospital: Suwon, Gyeonggi-do, KR

Korean Academy of Asthma Allergy and Clinical Immunology: Jongno-gu, Seoul, KR

Ajou University Hospital: Suwon, Gyeonggi-do, KR

The Korean Academy of Asthma, Allergy and Clinical Immunology : Seoul, KR

The Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI): Seoul, KR

The Korea Association of Internal Medicine: Seoul, KR

The Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI): Seoul, KR

The Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI): Seoul, Korea, KR

Ajou University Hospital: Suwon, Gyeonggi-do, KR

National Institutes of Health: Bethesda, MD, US

Ajou University Hospital: Suwon, Gyeonggi-do, KR

Ajou University Hospital: Suwon, Gyeonggi-do, KR

Ajou University Hospital: Suwon, Gyeonggi-do, KR

Yonsei University: Seoul, KR

Yonsei University: Seoul, KR

Yonsei University: Seoul, KR

Education and qualifications (3)

National Institutes of Health: Bethesda, MD, US

Yonsei University College of Medicine: Seodaemun-gu, Seoul, KR

Yonsei University College of Medicine: Seodaemun-gu, Seoul, KR

Funding (6)

Evaluation of immunostimulatory effect of intramuscular administration of autologous total IgG in human for development of a new immunotherapy

Development of a personalized immune-modulating therapy for patients with atopic dermatitis

Evaluation of clinical efficacy of autologous plasma therapy for atopic dermatitis

Evaluation of clinical efficacy and safety of allergen-immunotherapy for atopic dermatitis

Development and characterization of recombinant human autoantibody using cDNA made from peripheral blood mononuclear cells of patients with bronchial asthma

Role of autoimmune mechanism in the pathogenesis of nonallergic asthma

Works (50 of 53)

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

What are the clinical usefulness and scientific value of intramuscular injection of autologous serum (autologous serum therapy) in patients with atopic dermatitis?

Clinical efficacy and compliance of dupilumab therapy in adolescent and adult patients with atopic dermatitis in real clinical practice: An analysis of data from a single allergy clinic in Korea

Intramuscular Injection of Autologous Serum in Adolescent and Adult Patients with Atopic Dermatitis: A Preliminary Randomized Clinical Trial

Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance

Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives

Intramuscular administration of autologous total immunoglobulin G induces immunomodulatory effects on T cells in healthy human subjects

Clustering the Clinical Course of Chronic Urticaria Using a Longitudinal Database: Effects on Urticaria Remission

Erratum: Clustering the Clinical Course of Chronic Urticaria Using a Longitudinal Database: Effects on Urticaria Remission

Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response

Practical Insights into Atopic Dermatitis

Efficacy, Safety, and Immunomodulatory Effect of the Intramuscular Administration of Autologous Total Immunoglobulin G for Atopic Dermatitis: A Randomized Clinical Trial

Factors Associated with Adherence to Allergen Specific Subcutaneous Immunotherapy

Safety of Ultra-rush Schedule of Subcutaneous Allergen Immunotherapy With House Dust Mite Extract Conducted in an Outpatient Clinic in Patients With Atopic Dermatitis and Allergic Rhinitis

Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors

Immunomodulatory effects induced by intramuscular administration of autologous total immunoglobulin G in patients with atopic dermatitis

Textbook of Atopic Dermatitis

Clinical efficacy of subcutaneous allergen immunotherapy in patients with atopic dermatitis

Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: long-term changes of clinical severity and laboratory parameters

Effects of Intramuscular Injection of Autologous Immunoglobulin on Clinical Severity and Serum IgE Concentration in Patients with Atopic Dermatitis

Present and future of allergen immunotherapy for allergic diseases

Associations of atopic dermatitis with obesity and unmarried status in young adults: evidence for atopic dermatitis as a life-style disorder with high social impact.

Personalized immunomodulatory therapy for atopic dermatitis: An allergist’s View

Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: a preliminary report.

Clinical efficacy of autologous plasma therapy for atopic dermatitis.

Double-filtration plasmapheresis for the treatment of patients with recalcitrant atopic dermatitis.

A survey of the prescription patterns of allergen immunotherapy in Korea.

Treatment of severe atopic dermatitis with a combination of subcutaneous allergen immunotherapy and cyclosporin.

Asthma and Allergic Diseases

Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis

Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis.

Immunoglobulin G Subclass Deficiency is the Major Phenotype of Primary Immunodeficiency in a Korean Adult Cohort

Immunoglobulin G subclass deficiency is the major phenotype of primary immunodeficiency in a Korean adult cohort.

Mouse monoclonal autoantibodies penetrate mouse macrophage cells and stimulate NF-kappaB activation and TNF-alpha release.

Increased IgG antibody-induced cytotoxicity against airway epithelial cells in patients with nonallergic asthma.

Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex.

Antigen-binding characteristics of circulating IgG autoantibodies to cytokeratin 18 protein in patients with nonallergic asthma.

Identification of alpha-enolase as an autoantigen associated with severe asthma.

Allergy for 40 million Korean people

Korean Guideline for Treatment of Bronchial Asthma

Identification of Fyn-binding proteins in MC/9 mast cells using mass spectrometry

Asthma and Allergic disease

Identification of cytokeratin 18 as a bronchial epithelial autoantigen associated with nonallergic asthma